Condition: Healthy Adults · Sponsor: ANRS, Emerging Infectious Diseases
The SOLVE-01 trial is a study evaluating four SARS-CoV-2 vaccines as booster injections: two experimental vaccines (CD40.RBDv and CD40.Pan.CoV, both combined with the Hiltonol® adjuvant) and two authorised vaccines (Comirnaty® and NuvaxovidTM). This trial is designed for healthy adults aged 18 to 65 at the time of signing the informed consent form. The main objectives of this trial are: * to evaluate the safety of the two experimental vaccines, * to determine the antibody response induced by the vaccines and its durability. Participants will: * Receive one injection of vaccine and two intradermal skin tests * Come to the hospital 10 visits for medical exams and blood and saliva sample collection * Keep a diary of their symptoms and the treatments taken
This description comes directly from the study's public registry record.
Yves LEVY, Pr · +33(0)149814442 · yves.levy@aphp.fr
Giuseppe PANTALEO, Pr · +41(0)213141063 · Giuseppe.Pantaleo@chuv.ch
Always discuss trial participation with your own doctor first.
| Hôpital Henri Mondor | Créteil, France | Recruiting |
| CIC 1417 - Hôpital Cochin | Paris, France | Recruiting |
| Centre Hospitalier Universitaire Vaudois (CHUV) | Lausanne, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07605520